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ABSTRACT
Cancer stem cells have been shown to initiate and sustain
tumor growth. In many instances, clinical material is lim-
ited, compounded by a lack of methods to preserve such cells
at convenient time points. Although brain tumor-initiating
cells grown in a spheroid manner have been shown to main-
tain their integrity through serial transplantation in im-
mune-compromised animals, practically, it is not always
possible to have access to animals of suitable ages to contin-
uously maintain these cells. We therefore explored vitrifica-
tion as a cryopreservation technique for brain tumor-initi-
ating cells. Tumor neurospheres were derived from five
patients with glioblastoma multiforme (GBM). Cryopreser-
vation in 90% serum and 10% dimethyl sulfoxide yielded
greatest viability and could be explored in future studies.
Vitrification yielded cells that maintained self-renewal
and multipotentiality properties. Karyotypic analyses
confirmed the presence of GBM hallmarks. Upon implan-
tation into NOD/SCID mice, our vitrified cells reformed
glioma masses that could be serially transplanted. Tran-
scriptome analysis showed that the vitrified and nonvit-
rified samples in either the stem-like or differentiated
states clustered together, providing evidence that vitrifi-
cation does not change the genotype of frozen cells. Upon
induction of differentiation, the transcriptomes of vitri-
fied cells associated with the original primary tumors,
indicating that tumor stem-like cells are a genetically
distinct population from the differentiated mass, under-
scoring the importance of working with the relevant tu-
mor-initiating population. Our results demonstrate that
vitrification of brain tumor-initiating cells preserves the
biological phenotype and genetic profiles of the cells. This
should facilitate the establishment of a repository of tu-
mor-initiating cells for subsequent experimental designs.
STEM CELLS 2009;27:29–39
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
Cancers have long been regarded as morphologically heteroge-
neous masses of cells [1]. Cancer stem cells have been shown to
be responsible for tumor initiation and maintenance in many
neoplasms of the hematopoietic system, breast, brain, prostate,
colon, head and neck, and pancreas [2–10]. They have been
shown to possess chemoresistance and radioresistance proper-
ties [11–13], thus making them plausible candidates for the
perpetuation or recurrence of tumor growth following treatment
regimens. In many studies involving the prospective isolation of
tumor-initiating cells, only small amounts of clinical material
are available, and this limitation is compounded by a lack of
methods to preserve such cells at convenient time points. In
brain tumors, for instance, it has been demonstrated that in vivo
serial passage of tumor neurospheres (a heterogeneous mix of
stem and progenitor cells) can provide a means to reliably
maintain such primary cell lines [14]; however, in practice it is
not always possible to have access to immune-compromised
Author contributions: Y.-K.C., T.-B.T., S.H.L., and O.L.K.: collection and assembly of data, data analysis and interpretation; N.Z. and A.P.:
collection of data; C.E.L.O., Y.Y., P.B.T., and M.P.H.: collection and assembly of data; S.-J.S., W.-H.N., and I.N.: provision of study material
and patients; B.-T.A.: conception and design, financial support, provision of study material and patients, collection and assembly of data, data
analysis and interpretation, manuscript writing, final approval of manuscript; C.T.: conception and design, financial support, collection and
assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript. Y.-K.C. and T.-B.T., B.T.A., and C.T.
contributed equally to this work.
Correspondence: Carol Tang, Ph.D., Department of Research, National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433.
Telephone: 65-6357-7616; Fax: 65-6256-9178; e-mail: carolt@pacific.net.sg; Beng-Ti Ang, FRCS(SN) Department of Neurosurgery,
National Neuroscience Institute, 11 Jalan Tan Tock Seng, Singapore 308433. Telephone: 65-6357-7627; Fax: 65-6357-7137; e-mail:
Beng_Ti_Ang@nni.com.sg Received January 6, 2008; accepted for publication September 22, 2008; first published online in STEM CELLS
EXPRESS October 9, 2008; available online without subscription through the open access option. ©AlphaMed Press 1066-5099/2008/$30.00/0
doi: 10.1634/stemcells.2008-0009
CANCER STEM CELLS
STEM CELLS 2009;27:29–39 www.StemCells.comanimals of suitable ages to continuously maintain the stem and
progenitor cells. Lee et al. showed that tumor stem-like cells
grown in serum-free conditions closely mimic the genotype,
gene expression profile, and biology of their parental tumors
[15]. These observations bring into question the relevance of
standard serum-grown cancer cell lines for studying the biology
of human cancer and for screening new therapeutic agents. We
therefore sought to explore a novel method of vitrification for
brain tumor neurospheres that is effective at preserving the
cells’ biological and genetic properties. We believe the method
could provide many researchers with the means to establish a
repository of primary brain tumor-initiating cells that can
readily be tapped upon for expansion or experimental designs.
Vitrification has been commonly used in the preservation of
cells involved in reproduction [16, 17], human embryonic stem
cell bodies [18], and cell-containing constructs used in tissue
engineering [19]. Vitrification is preferred over conventional
slow-cooling methods for several reasons (reviewed in [20]),
with one central dogma: when thawed, cells should remain
viable and maintain their biological profiles. Here, we report the
development of a modified vitrification technique applied to
long-term cryopreservation of brain tumor neurospheres derived
from human adult malignant glioblastoma multiforme (GBM).
We propose a method whereby vitrification can be combined
with in vivo serial passaging to establish a repository of tumor-
initiating cells that should facilitate future investigative work.
MATERIALS AND METHODS
Tissue Collection and Primary Neurosphere Culture
Graded brain tumor specimens were obtained with informed con-
sent, as part of a study protocol approved by the institutional review
board. In this study, S0305 was from a patient with recurrent GBM
(grade IV) who had received radiation therapy, and S0405, S0805,
S0306, and S0807 were from patients with primary GBM who were
treatment-naive. Tumors were processed according to Gritti et al.
[21] with slight modifications. Cells were seeded at a density of
2,500 cells per cm
2 in chemically defined serum-free selection
growth medium consisting of basic fibroblast growth factor, basic
fibroblast growth factor (bFGF; 20 ng/ml; Chemicon, Temecula,
CA, http://www.chemicon.com), epidermal growth factor (EGF; 20
ng/ml; Chemicon), human recombinant leukemia inhibitory factor
(LIF; 20 ng/ml; Chemicon), heparin (5 g/ml; Sigma-Aldrich, St.
Louis, http://www.sigmaaldrich.com), and serum-free supplement
(B27; 1; Gibco, Grand Island, NY, http://www.invitrogen.com) in
a 3:1 mix of Dulbecco’s modified Eagle’s medium (DMEM; Sigma-
Aldrich) and Ham’s F-12 Nutrient Mixture (F12; Gibco). The
cultures were incubated at 37°C in a water-saturated atmosphere
containing 5% CO2 and 95% air. To maintain the undifferentiated
state of neurosphere cultures, growth factors were replenished every
2 days. Differentiation was carried out over 14 days in DMEM/F12
without growth factors, supplemented with 5% fetal bovine serum
(FBS) and B27. Successful neurosphere cultures (1–4 weeks) were
expanded by mechanical trituration using a flame-drawn glass Pas-
teur pipette, and cells were reseeded at 100,000 cells per milliliter in
fresh medium.
Cryopreservation and Thawing of Neurosphere
Cultures for Viability Count
In the conventional cryopreservation method, 5,000 neurospheres
(50–100 m) were frozen in a slow-cooling protocol using a
freezing container (Mr. Frosty; Nalgene Nunc International, Roch-
ester, NY, http://www.nalgenelabware.com) in 80°C for 24 hours
before transfer into 196°C liquid nitrogen storage for 30 days.
Freezing media used contained DMEM/F12 supplemented with
10% dimethyl sulfoxide (DMSO; Merck & Co., Whitehouse Sta-
tion, NY, http://www.merck.com) only, or 10% DMSO and 90%
FBS (HyClone, Logan, UT, http://www.hyclone.com). These sam-
ples were thawed at 37°C in a water bath for 1–2 minutes and
washed with excess DMEM/F12 before being cultured in chemi-
cally defined serum-free selection growth medium supplemented
with growth factors (DMEM/F12; 20 ng/ml each of EGF, bFGF,
and LIF; B27; and 5 g/ml heparin). Viability counts were carried
out after incubation periods of 1, 5, and 10 days [22].
In the vitrification method, tumor neurospheres from the same
passage were subjected to either vitrification or continuous cultur-
ing (nonvitrified). Five thousand neurospheres (50–100 m) were
frozen in a rapid cooling protocol. Neurospheres were resuspended
in a holding medium (HM) of DMEM/F12 containing HEPES
buffer (Gibco) with or without 20% FBS before being transferred by
pipetting into sequentially increasing concentrated vitrification so-
lutions (VS1 and VS2). Neurospheres were incubated for 1 minute
in VS1 consisting of 10% DMSO and 10% ethylene glycol (EG)
(Merck), followed by a 25-second incubation in VS2 consisting of
20% DMSO, 20% EG, and 0.3 M sucrose. The mixture was imme-
diately transferred into 0.78-mm inner diameter borosilicate glass
capillaries (Harvard Apparatus, Holliston, MA, http://www.
harvardapparatus.com), snap-frozen, and stored in liquid nitrogen.
All procedures were performed in an aseptic manner at room
temperature.
The following periods of freezing for vitrified cultures were
evaluated prior to thawing: S0305 and S0405 for 30 days, S0807 for
8 months, S0306 for 1.5 years, and S0805 for 2.5 years. Thawing
was performed in sucrose solutions (SS) of sequentially decreasing
concentrations (SS1 and SS2). After removal from liquid nitrogen,
the contents of the glass capillaries were released by reverse capil-
lary action into SS1 containing HM supplemented with 0.2 M
sucrose for 1 minute. They were then transferred by pipetting into
SS2 containing HM supplemented with 0.1 M sucrose and incu-
bated for 5 minutes, followed by another 5 minutes in HM alone.
The mixture was washed with excess HM before being cultured in
chemically defined serum-free selection growth medium supple-
mented with growth factors at the above-mentioned concentrations
(DMEM/F12, EGF, bFGF, LIF, B27, and heparin). Viability counts
were carried out after incubation periods of 1, 5, and 10 days [22].
Immunofluorescence Analyses
Neurospheres from vitrified and nonvitrified conditions were dis-
sociated into single cells using Accutase (eBioscience Inc., San
Diego, http://www.ebioscience.com; non-trypsin-based) and seeded
at a cell density of 2  10
5 cells per well of laminin-coated
(Sigma-Aldrich) eight-well culture slides (BD Falcon, Bedford,
MA, http://www.bdbiosciences.com). Plated cells were then stained
for the following markers.
Stemness Markers. The undifferentiated cells (stem state) were
stained for Nestin (Chemicon), Oct-4 (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, http://www.scbt.com), Musashi-1 (Chemi-
con), and Ki-67 (Chemicon). Incubation with a secondary antibody
conjugated to Alexa-Fluor (Molecular Probes, Eugene, OR, http://
probes.invitrogen.com) was carried out.
Multipotentiality Markers. Induction of differentiation was car-
ried out with DMEM/F12 in the absence of growth factors and
supplemented with 5% FBS and 1 B27. On day 14, differentiated
cells were stained for neurons (neuron-specific class III beta-tubulin
[TuJ1]; Chemicon), astrocytes (glial fibrillary acidic protein
[GFAP]; Dako, Glostrup, Denmark, http://www.dako.com), and
oligodendrocytes (O4; Chemicon).
Secondary Sphere Formation Assays
Tumor neurospheres were dissociated into single cells by treatment
with Accutase (eBioscience). The cells were then dispensed into
each well of a 96-well plate at decreasing cell numbers of 100, 80,
60, 40, and 20. Sphere formation was scored at day 7 after seeding.
To carry out sequential minimal dilution assays, the secondary
spheres were similarly dissociated into single cells and then dis-
pensed into each well of a 96-well plate at similar decreasing
numbers. Tertiary sphere formation was scored on day 7 after
seeding. Sequential minimal dilution experiments were carried out
for at least three passages.
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Neurospheres were dissociated with Accutase (eBioscience) and
stained with anti-CD133/2-allophycocyanin according to the man-
ufacturer’s instructions (Miltenyi Biotec, Bergisch Gladbach, Ger-
many, http://www.miltenyibiotec.com). Dead cells were distin-
guished by propidium iodide staining. A total of 10,000 events was
acquired on a FACSCalibur instrument (BD Biosciences, San Di-
ego, http://www.bdbiosciences.com). Data were plotted using
FlowJo software (Tree Star, Ashland, OR, http://www.treestar.
com).
Karyotypic Analyses of Tumor Neurospheres
Five thousand cells from triturated neurospheres were cultured in
the stem state on a laminin-coated culture-well slide. The cells were
then treated within 3–5 days with 0.1 g/ml colcemid (Invitrogen,
Carlsbad, CA, http://www.invitrogen.com) for 24 hours, followed
by 0.075 M KCl, and fixed in methanol:acetic acid (3:1). Meta-
phase-fluorescent in situ hybridization (mFISH) (MetaSystems
XCyte mFISH; MetaSystems GmbH, Heidelberg, Germany, http://
www.metasystems.de) and spectral karyotyping (SkyPaint; Applied
Spectral Imaging, Israel, http://www.spectral-imaging.com) were
performed on metaphases according to the manufacturers’ instruc-
tions.
Microarray Analysis and Quantitative Real-Time
Polymerase Chain Reaction
Total RNA was isolated from neurosphere cells using Trizol (In-
vitrogen) and purified with the RNeasy Mini Kit (Qiagen, Hilden,
Germany, http://www1.qiagen.com). Reverse transcription and
cRNA amplification were performed using an RNA Amplification
kit (Ambion, Austin, TX, http://www.ambion.com). The microarray
hybridization was performed using the Illumina Gene Expression
BeadChip (Illumina Inc., San Diego, http://www.illumina.com), and
data analysis was performed using GeneSpring software (Agilent
Technologies, Palo Alto, CA, http://www.agilent.com).
Real-time polymerase chain reaction (PCR) was carried out
according to the manufacturer’s protocol for the LightCycler Fast-
Start MasterPLUS SYBR Green I real-time PCR kit (Roche Diag-
nostics, Basel, Switzerland, http://www.roche-applied-science.
com). A standardized amount of 50 ng of cDNA was used for each
PCR. The PCR was carried out with specific oligonucleotide primer
pairs at the optimized annealing temperatures stated (supporting
information Table 1). Cycle parameters on the LightCycler (Roche
Diagnostics) were 40 cycles of 95°C for 10 seconds, 55°C for 10
seconds, and 72°C for 5 seconds. Each real-time PCR was done in
triplicate, and the level of expression of each gene was determined
relative to the normalizer gene glyceraldehyde-3-phosphate dehy-
drogenase.
Stereotaxic Intracranial Implantations of NOD/SCID
Mice
Tumorigenicity was determined by injecting GBM cells from dis-
sociated neurospheres orthotopically in nonobese diabetic/severe
combined immunodeficiency (NOD/SCID) mice. Two hundred
thousand cells in 5 l of phosphate-buffered saline were delivered
into the right frontal lobe (0.5 l/minute) by stereotaxic injection
through a glass electrode connected to a Hamilton syringe (Narish-
ige, Tokyo, http://www.narishige.co.jp/main.htm). The following
coordinates were used: anteroposterior, 2 mm; mediolateral, 2
mm; dorsoventral, 3 mm. Mice were euthanized by means of
transcardiac perfusion with 4% paraformaldehyde upon presenta-
tion of neurological deficits with ataxia, cachexia, lethargy, or
seizure [23]. Hematoxylin and eosin staining and immunohisto-
chemistry were performed on 5-m-thick paraffin sections. Sec-
tions were processed as described by Vescovi et al. [24]. Mouse
anti-human vimentin antibody staining (clone V9; Zymed Labora-
tories, San Francisco, http://www.invitrogen.com) was used to con-
firm the presence of engrafted human cells.
Statistical Analysis
Data are expressed as means  SEM of at least three independent
experiments. Student’s t test or the Mann-Whitney U test was used
where appropriate. p  .05 was accepted as statistically significant.
RESULTS
Vitrification Maintains the Morphology and
Viability of Progenitor-Like Cells
To assess the effectiveness of vitrification over conventional
slow-cooling methods, we analyzed essential properties, such as
viability, expression of stem cell markers, and multipotentiality.
All patients’ lines generated free-floating neurospheres except
for S0306, which generated semiadherent spheres. GBM neu-
rospheres were frozen either conventionally in a slow-cooling
protocol with 10% DMSO in the presence or absence of 90%
FBS, or vitrified in low serum-containing or serum-free medium
by exposing glass capillaries containing neurosphere clumps to
liquid nitrogen. The cell clumps were then stored in liquid
nitrogen for 30 days to as long as 2.5 years to mimic long-term
storage prior to analyses.
We assessed the viability of tumor neurospheres at 1, 5, and
10 days after thawing from liquid nitrogen storage by counting
the number of neurospheres measuring at least 50–100 mi n
diameter [22]. Neurosphere formation had previously been
shown to indicate viability and proliferation [25, 26]. A visual
scan of cellular morphology indicated that vitrification with low
serum best maintains initial frozen neurosphere size with little
or no cell death, with cells remaining relatively undifferentiated
for up to 15 days in culture (Fig. 1Ai–1Aiii, 1B). Cryopreser-
vation by vitrification lacking serum or by standard freezing
with 10% DMSO showed greater cell death and vastly smaller
neurospheres compared with nonvitrified cultures, suggesting
disintegration of sphere structures (Fig. 1Aiv–1Aix). We could
not recover sufficient cells for further analysis due to extensive
cell death. Standard freezing with 90% FBS yielded the best
viability and preservation of sphere structures for all samples
except S0405, where vitrification with serum yielded the best
viability (Fig. 1Bii). However, the peripheries of all tumor
spheres cryopreserved in 90% FBS exhibited clear signs of
differentiation by 5 and 10 days post-thawing (Fig. 1Axi, 1Axii,
arrows; Fig. 1B). Our finding indicates that freezing with 90%
serum and 10% DMSO is an attractive alternative that should be
explored in future studies. Encouraged by the good viability and
lack of differentiation demonstrated by vitrified tumor spheres,
we proceeded with our analyses by comparing vitrified and
nonvitrified samples.
Vitrification Maintains the Proliferation Rate of
Tumor Neurospheres
A key criterion for efficacious vitrification is the preservation of
cellular properties upon thawing when compared with their
corresponding nonvitrified samples. Proliferation assays
showed that all vitrified and nonvitrified tumor neurospheres
continued to proliferate at similar rates except for S0805, which
displayed a moderate but significant change (Fig. 1C).
Vitrification Preserves the Stemness Expression and
Multipotentiality of Tumor Neurospheres
Markers of the stemness state, such as Nestin, Sox-2, CD133,
Musashi-1 (Msi-1), Bmi-1, Nanog, and Oct-4, were assayed by
quantitative real-time PCR. Differentiation markers, such as TuJ1,
myelin-associated oligodendrocyte basic protein (MOBP), and
GFAP, were also evaluated, as neurospheres are heterogeneous
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Figure 1. Vitrification results in greater viability and maintains proliferative capacity of tumor neurospheres. Tumor neurospheres were frozen by various
methods: vitrification with 20% serum (Ai–Aiii), vitrification without serum (Aiv–Avi), 10% DMSO (Avii–Aix), and 90% FBS (Ax–Axii). After storage
in liquid nitrogen for 30 days (vitrification with and without serum, 10% DMSO, and 90% FBS) and up to 2.5 years (vitrification with serum only), the
neurospheres were thawed and subjected to morphological analyses while in culture under serum-free conditions supplemented with growth factors. Shown
are representative images obtained from one patient’s neurosphere line, S0305. Note the appearance of extended processes at the periphery (typical of
differentiation) on days 5 and 10 of the sample frozen with 90% FBS (arrows). Scale bars  100 m. (B): Morphological analyses in (A) were quantified.
(A, B): Experiments carried out in duplicate. (C): Patients’ tumor neurospheres were subjected to vitrification, and proliferation rate using a standard
AlamarBlue assay (AbD Serotec, Oxford, United Kingdom, http://www.ab-direct.com) was determined after thawing. S prefix represents tumor neuro-
spheres, and numbers represent codes assigned to specimens (, p  .05). Abbreviations: DMSO, dimethyl sulfoxide; FBS, fetal bovine serum; Vit. FBS,
vitrification with fetal bovine serum.
32 Cryopreservation of Human Tumor Neurospheresand comprise more differentiated progenitors, in addition to
stem cells [27, 28]. Nestin is expressed in neural precursors
[29]; Sox-2 is a gene known to play a role in maintenance of the
neural progenitor state [30]; CD133 is a marker for neural stem
cells, as well as brain tumor stem cells [10, 31]; Msi-1 is a
marker for self-renewal [32]; Bmi-1 is a Polycomb group gene
and epigenetic silencer that prevents premature growth arrest in
most differentiated tissue cells and is essential for the self-
renewal of several types of adult stem cells [33, 34]; Nanog is
a transcription factor essential for the maintenance of an undif-
ferentiated state [35]; and Oct-4 is a transcription factor impli-
cated in maintaining the pluripotency of stem cells [36, 37].
TuJ1 marks neurons, MOBP marks oligodendrocytes, and
GFAP marks astrocytes. Vitrification preserved the expression
of essential stem cell markers for samples S0405, S0306, and
S0807 (Fig. 2). Between vitrified and nonvitrified samples,
expression of Nestin, CD133, Bmi-1, Nanog, and TuJ1 for
S0305 were minimally altered, by less than twofold (Fig. 2B),
but there was significant variation in virtually all genes exam-
ined for S0805 (Fig. 2E).
We carried out immunofluorescent staining experiments to
verify the stemness and multipotentiality profiles of vitrified and
nonvitrified samples. All patients’ tumor neurospheres demon-
strated preservation of stem-like cells in vitrified and nonvitri-
fied samples (Fig. 3A, top panel; Fig. 3Bi; supporting informa-
tion Fig. 1A; supporting information Table 2A). As cell
morphology changes accompany the induction of differentiation
of neural stem cells, we assessed multipotentiality by scoring for
neurons (TuJ1), astrocytes (GFAP), and oligodendrocytes (O4).
All samples displayed the ability to differentiate into neurons,
astrocytes, and oligodendrocytes (Fig. 3A, lower panel; Fig.
3Bii; supporting information Fig. 1B; supporting information
Table 2B). In addition, we scored for differentiated cells stain-
ing positively for Nestin and Msi-1 stemness markers. We also
scored for cells coexpressing GFAP and TuJ1. All patients’
neurospheres, when differentiated, showed no significant differ-
ences between the vitrified and nonvitrified states, supporting
the idea that vitrification preserves the multipotentiality prop-
erty of the cells (supporting information Table 2B). We ob-
served that all samples displayed 70%–95% Nestin- and Msi-
1-stained cells despite being cultured under differentiating
conditions, indicating the retention of self-renewal potential in
otherwise normally terminally differentiated cells (Fig. 3A,
lower panel; supporting information Table 2B). Work by several
other investigators has also documented this phenotype [38, 39].
This may in turn reflect an aberrant regulatory pathway in
cancer stem cells. Differentiated cells were detected that
costained for GFAP and TuJ1; notably, S0306 differentiated
cells expressed the highest proportion of such cells (Fig. 3A,
lower panel; supporting information Table 2B). Previous work
by others has also demonstrated the coexistence of such nor-
mally distinct neural developmental pathways [14, 38–40];
these pathways may characterize an abnormality in tumor-initi-
ating cells.
Vitrified Tumor Neurospheres Demonstrate
Secondary Sphere Formation and Self-Renewal
Potential
To investigate the stem cell frequency and self-renewal potential
of our tumor neurospheres, we dissociated neurospheres into
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Figure 2. Vitrification preserves essential neural precursor gene expression. (A–E): Quantitative real-time polymerase chain reaction analysis of five
patients’ tumor neurospheres. The undifferentiated states of both vitrified and nonvitrified neurospheres were analyzed for the presence of
stem/progenitor and differentiation markers (, p  .05; , p  .01). Abbreviations: GFAP, glial fibrillary acidic protein; MOBP, myelin-associated
oligodendrocyte basic protein; Msi-1, Musashi-1; TuJ1, neuron-specific class III beta-tubulin.
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www.StemCells.comsingle cells, dispensed them into 96-well plates at decreasing
cell numbers, and then scored them for secondary sphere for-
mation after 7 days (Fig. 4A; supporting information Fig. 2A).
Cell clustering played no apparent role in sphere formation, as
cells were plated at clonal densities [14]. As neurospheres are
heterogeneous and the neurosphere assay does not distinguish
initially proliferating neural precursors from bona fide stem
cells with self-renewal potential [27, 28], we sought to carry out
sequential minimal dilution assays for at least three passages,
which confirmed that these single-cell-derived tumor spheres
possessed the potential to grow infinitely, underscoring self-
renewal as an important criterion for brain tumor-initiating cells
[41]. The proportion of sphere-forming cells remained stable
throughout the course of culture (6 months), indicating asym-
metrical cell divisions. There was no significant difference
noted between the vitrified and nonvitrified samples of all
patients’ tumor neurosphere lines except for S0805, indicating
that the vitrification procedure does not reduce the secondary
sphere-forming ability of these cells (Fig. 4A; supporting infor-
mation Fig. 2A). Moreover, the CD133-expressing population
within the spheres that is often associated with tumor-initiating
potential [10, 42, 43] was also maintained throughout the course
of culture (6 months; Fig. 4B; supporting information Fig.
2B).
Vitrification Preserves the Karyotypic Hallmarks of
Glioblastoma Multiforme
To further demonstrate the tumor origin of our spheres, as well as
to ascertain that vitrification itself preserves the karyotypic integrity
and hallmarks of GBM, we karyotyped all patients’ neurospheres
before and after the vitrification process. Our data indicate that all
spheres were of tumor origin and preserved their karyotypic integ-
rity, as well as maintaining the hallmarks of GBM, in both vitrified
and nonvitrified samples (Fig. 5; supporting information Fig. 3).
Notably, polysomy of chromosome 7 and loss of chromosome 10
were present. This is consistent with a previous report by Singh et
al. [10]. In addition, we observed aneusomy of chromosomes 12
and 13 across all five patients’ tumor neurospheres. S0805 nonvit-
rified cells exhibited an altered karyotype compared with vitrified
cells (supporting information Fig. 3C). As S0805 nonvitrified cells
had been in vitro passaged for the longest period compared with all
other lines (more than 50 passages), it is probable that this resulted
in changes in proliferation rate, self-renewal potential, and gene
expression, as previously shown.
Tumor Neurospheres Re-Create Glioma
Pathophysiology in NOD/SCID Mice
The abilities to recapitulate tumor pathophysiology in an immune-
compromised animal model and to serially transplant the tumor
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Figure 3. Vitrification preserves stemness and differentiation marker expression. (A): Immunofluorescent staining of representative sample S0305
with stem cell/precursor markers (Nestin, Msi-1, Oct-4, and Ki-67) (top panel) and multipotentiality markers (TuJ1, GFAP, and O4) (bottom panel).
(Bi): Quantification of data in (A), top panel. (Bii): Quantification of data in (A), bottom panel. p  .05 for all samples pairs, indicating that there
was no significant difference between vitrified and nonvitrified samples. Data for all other tumor neurosphere lines are available supporting
information Figure 1A, 1B, and supporting information Table 2. Abbreviations: GFAP, glial fibrillary acidic protein; Msi-1, Musashi-1; TuJ1,
neuron-specific class III beta tubulin.
34 Cryopreservation of Human Tumor Neurospheresprovide unequivocal evidence for the function of a cancer stem cell
[41]. Importantly, when our vitrified tumor neurospheres grown
under serum-free conditions were orthotopically implanted in
NOD/SCID mice, tumor xenografts formed that recapitulated gli-
oma pathophysiology. The intracranial tumors of S0305 and S0405
demonstrated extensive infiltration into the surrounding cerebral
cortex, a pathognomonic feature of human GBMs [10, 14] (Fig.
6A). Tumors formed by S0805 and S0807 were smaller in size due
to an earlier period of sacrifice but nevertheless demonstrated
similar infiltrative margins [22]. S0306 cells formed a tumor that
exhibited a well-circumscribed margin (data not shown). These
tumors were also serially transplantable in secondary recipients for
two of the lines tested (two of three mice; S0305 and S0405),
conclusively demonstrating the in vivo self-renewal potential of
GBM-derived tumor-initiating cells. In contrast, mice implanted
with serum-grown cells generated spatially constrained gliomas
with clear delineated margins, nonreflective of actual glioma
growth patterns (data not shown) [15]. This underscores the im-
portance of using tumor neurospheres grown in serum-free condi-
tions as the relevant model for further investigations.
Gene Expression Studies Demonstrate the Clustering
of Vitrified and Nonvitrified Samples and
Distinguish Tumor Spheres from Their
Differentiated Forms and Primary Tumors
If vitrification is to be an efficient method for cryopreserving
tumor-initiating cells, then we expect that vitrified and nonvit-
rified samples should generate transcriptome profiles that clus-
ter together, indicating the genetic stability of the samples. We
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Figure 4. Tumor spheres possess self-renewal capability and maintain
CD133 subpopulation. (A): Neurospheres were dissociated into single cells,
plated at decreasing cell numbers, and analyzed for their ability to form
secondary neurospheres. Representative plots are shown for two samples,
S0305 and S0405. p  .05 for all sample pairs, indicating that vitrified and
nonvitrified samples maintained self-renewal capability. Data for all other
samples are shown in supporting information Figure 2A. (B): Tumor
neurospheres were dissociated into single cells and stained with anti-
CD133/2 antibody conjugated to APC according to the manufacturer’s
instructions (Miltenyi Biotec). CD133 percentage was determined by flu-
orescence-activated cell sorting. Each vitrified or nonvitrified sample was
gated according to its own matched isotype control. Shown are represen-
tative plots of two patients’ glioblastoma multiforme spheres, S0305 and
S0405. Data for all other samples are shown in supporting information
Figure 2B. Abbreviation: APC, allophycocyanin.
Figure 5. Vitrified neurospheres maintain karyotypic integrity and
glioblastoma multiforme hallmarks. Single 2  10
5 cells from dissoci-
ated neurospheres were karyotyped by metaphase-fluorescent in situ
hybridization (mFISH) analyses according to the manufacturer’s in-
structions (MetaSystems XCyte mFISH). Arrows point to polysomy of
chromosome 7 and loss of chromosome 10. Asterisks indicate aneusomy
of chromosomes 12 and 13. Data for all other neurosphere lines are
shown in supporting information Figure 3.
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patients’ tumor neurosphere lines (vitrified and nonvitrified), as
well as on their differentiated progenies (vitrified and nonvitri-
fied) and primary tumor specimens. Indeed, unsupervised clus-
ter analysis showed that the vitrified form of each sample in
either the stem/progenitor or differentiated state clustered to-
gether with its respective nonvitrified form (Fig. 7A, 7B). This
supports our finding that vitrification preserves the genetic
profile of brain tumor-initiating cells. An exception was S0807;
the transcriptome profile of the differentiated form resembled
that of the S cluster. Upon induction of differentiation, S0807
cells tended to grow in compact patches compared with all other
samples (unpublished observations); thus, it is plausible that
they remained relatively undifferentiated, resulting in a tran-
scriptome that resembled that of the stem-like cells. In addition,
tumor neurospheres consisting of stem and progenitor cells were
also genetically distinct from their differentiated forms and
primary tumors. S0306 undifferentiated spheres however clustered
with the primary tumors. We believe this reflects a different phe-
notypic and genotypic subtype of GBM neurospheres [22, 44].
DISCUSSION
Tissue repositories have traditionally been maintained either as
frozen samples stored in liquid nitrogen tanks, or embedded in
paraffin wax. Although both methods of storage allow the
retrieval of cellular material, it does not allow the isolation and
subsequent cultivation of live cells from the stored tumor. In this
study, we present data for the first time on a modified vitrifi-
cation method for human brain tumor neurospheres that enriches
for tumor-initiating cells, more commonly referred to as cancer
stem cells. Such a method evaluates essential stem cell-like
properties, multipotentiality capacity, genotypic profile, and
ability to recapitulate glioma pathophysiology. Vitrification
now provides a solution to the long-term storage of tumor-
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Figure 6. Vitrified glioblastoma multiforme spheres form tumor xenografts that recapitulate glioma pathophysiology. Two hundred thousand cells
from dissociated tumor neurospheres were stereotaxically implanted into NOD/SCID mice. Animals were sacrificed by transcardiac perfusion upon
presentation of neurological deficits. A representative tumor xenograft created from S0305 cells is shown. Tissue sections were stained with
hematoxylin and eosin (Ai). The presence of human cells in tumor xenografts was confirmed by staining with an anti-human vimentin antibody (clone
V9; Zymed Laboratories) (Aii). (Ai) represents the glioma mass formed (asterisk denotes interhemispheric fissure). Note the infiltrative tumor margin
in (Aiii). (B): A model is illustrated in which vitrification can be combined with in vivo serial passaging to maintain a repository of brain
tumor-initiating cells. We propose that the vitrification method can be used at indicated stages (red) to cryopreserve tumor-initiating cells. These cells
can subsequently be thawed and expanded at a later stage for biological assays, such as drug screening, or subjected to serial passaging in NOD/SCID
mice. Vitrification permits long-term storage of such cells without changes to their genotypic and functional properties. Abbreviation: T, tumor mass.
36 Cryopreservation of Human Tumor Neurospheresinitiating cells without the need to maintain a constant supply of
immune-compromised animals of suitable ages to in vivo serially
passage the cells. With the vitrification approach, a glass-like
solidification of the freezing solution is achieved by using a high
concentration of cryoprotectant and rapid cooling. This method
eliminates cell injury due to ice crystal formation. Although various
cryopreservation techniques have been developed for a range of
cells, such as human/mouse embryonic stem cells [18, 45] and
mouse neural precursor cells [46–48], these studies have largely
relied on gross morphological appearances and have ignored ex-
amining the genetic profiles and quantitative analysis of cell types
(both stem and differentiated forms) of samples. For validation of
vitrification as a method of cryopreservation for brain tumor-
initiating cells, the cellular heterogeneity of tumor cells and their
ability to recapitulate glioma pathophysiology would have to be
taken into consideration.
Standard freezing techniques with high serum content have
been used in many cellular systems because of their less com-
plex preparatory steps. Previous work has evaluated the use of
such a method in the cryopreservation of human embryonic
stem cells, which resulted in differentiated outgrowths [45].
Here, we demonstrate that although freezing with 90% FBS
yielded the best viability of tumor neurospheres, it also resulted
in differentiated outgrowths. Serum contains many unknown
growth factors or cytokines that can induce differentiation of
stem cells when applied at high concentrations [45, 49]. Nev-
ertheless, given the significantly better viability, slow freezing
with high serum presents an attractive alternative that should be
explored in future studies. We show that vitrification maintains
essential stem/progenitor-like properties, multipotentiality, and
genotypic profiles. Importantly, the vitrified cells retain the
capacity to form tumor xenografts that recapitulate glioma
Figure 7. Vitrification preserves genetic
profiles of glioblastoma multiforme spheres,
which are genetically distinct from primary
tumors and differentiated cells. (A): Dendro-
gram determined by unsupervised hierarchi-
cal cluster analysis of all patients’ tumor
neurospheres (V and NV) cultivated under
serum-free conditions supplemented with
growth factors (S-suffix) or differentiated by
withdrawal of growth factors with addition
of serum (D-suffix). Samples with the T-
suffix represent the original primary tumor
specimen. Numbers represent codes as-
signed to specimens. (B): PCA of all sam-
ples in (A) showing the distinct genetic pro-
files of S, D, and T clusters. S0306 tumor
spheres associated with the T cluster. Abbre-
viations: D, differentiated; NV, nonvitrified;
PCA, principal component analysis; S, se-
rum-free; T, tumor; V, vitrified.
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GBM-derived tumor-initiating cells, we performed sequential
transplantation experiments. This was done in analogy with the
classic hematopoietic serial repopulation paradigm used to identify
true hematopoietic stem cells [50]. The successful, sequential gen-
eration of brain tumors provides evidence that we have isolated and
maintained bona fide tumor-initiating cells [41].
Our microarray gene expression data indicate the clustering
of vitrified and nonvitrified samples in each tumor specimen,
consistent with this freezing technique maintaining the genetic
profiles of the tumor neurospheres. To our surprise, the S0805
nonvitrified sample, which we previously concluded to have
undergone changes due to prolonged in vitro expansion, now
clustered with its vitrified form. Lee et al. [15] demonstrated the
genetic stability of tumor neurosphere lines growing in culture
for more than 70 passages by examining their transcriptome
profiles. We believe that although transcriptome profiles reflect
overall gene transcript changes, one needs to exercise caution in
extrapolating the data to indicate stability of cell lines. Impor-
tantly, parallel analyses of a combination of essential stem cell
characteristics should be performed to evaluate the quality of a
tumor neurosphere line.
We observed that S0306 spheres generated a profile distinct
from all other tumor sphere samples and instead associated more
closely with primary tumors. Interestingly, S0306 spheres dis-
played semiadherent growth patterns compared with all other
free-floating spheres. This is consistent with the presence of
tumor sphere subtypes as previously reported [22, 44]. Gu ¨nther
et al. [22] was able to ascertain that the gene expression profile
of the semiadherent spheres contained genes more commonly
expressed in GBM tumor tissue specimens. This is in contra-
distinction with the profiles of free-floating spheres. Indeed, the
genetic profile of S0306 spheres was associated more closely
with that of primary tumors (Fig. 7B).
We highlight that although primary tumors containing a mix
of different cell types can display transcriptome profiles that
associate closely with each other (Fig. 7B, S0306T and
S0305T), the genetic profiles of their presumed cell of origin
(S0306-S and S0305-S) can be significantly different. This may
reflect a limitation in evaluating a heterogeneous tumor mass as
opposed to a population enriched for tumor-initiating cells. In
gene expression studies, Lee et al. [15] reported that tumor
spheres clustered together with parental tumor samples, and this
clustering differed as matched samples were differentiated in
serum-containing media. They inferred that because tumor
spheres contained gene expression and biology similar to those
of parental tumors, the tumor spheres therefore represented a
more reliable model system compared with serum-grown cancer
cells. We believe that in the cluster analysis, the tumor spheres
clustering together with the parental tumors would depend on
the abundance of tumor stem/progenitor cells in the parental
tumor. If cancer stem-like cells form only a minority of the
parental tumor, this clustering would not be evident. Indeed,
work by Clement et al. [51] showed the stemness signature
associating more closely with grade III astrocytomas than with
grade IV GBM tumors. In our study, our parental tumors clus-
tered more closely with the differentiated forms, likely indicat-
ing that the parental tumors that we collected contained more
differentiated cells. Importantly, we have shown that our tumor
spheres were able to reform tumor xenografts in NOD/SCID
mice that recapitulated glioma pathophysiology (Fig. 6A), thus
confirming their identity as tumor-initiating cells [14]. These
spheres were also more resistant to the effects of temozolomide
(a commonly used clinical drug) compared with serum-grown
glioma cells (supporting information Fig. 5), thereby underscor-
ing the significance of focusing on this cellular subpopulation.
CONCLUSION
Our data illustrate for the first time that tumor stem-like cells are
genetically distinct from their differentiated forms, which in turn
associate more closely with the parental tumors. This highlights
the significance of designing therapeutic agents targeted at the
relevant minority tumor-initiating population in addition to tar-
geting the other majority more differentiated tumor mass. Pro-
longed in vitro culturing of S0805 tumor neurospheres resulted
in karyotypic, genotypic, and phenotypic changes, further high-
lighting the importance of our vitrification technique in cryo-
preserving such cells at early passages of primary culture estab-
lishment. Our method may be applicable to other neoplastic
stem-like cells grown in a spheroid manner, such as those
isolated from the breast (mammospheres) [52, 53], prostate
(prostaspheres) [54, 55], head and neck [56], and lung [57]
cancers. These spheres have been shown to be of clonal origin
and to derive from primitive cells. More importantly, they can
be dissociated and passaged for more than 10 generations,
suggesting the existence of a population of cells with extensive
self-renewal capacity. Our work therefore supports the use of
the vitrification procedure in establishing a brain tumor-initiat-
ing cell repository for facilitating further investigative work
focused on this cellular subpopulation, and possibly for future
drug targets. We envisage that a combination of vitrification and
in vivo serial passaging in NOD/SCID mice will provide a
convenient means of preserving the tumor-initiating population
(Fig. 6B).
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